Adiponectin predicts MMP-2 activity independently of obesity
Background Matrix metalloproteinases (MMPs), especially MMP‐2 and MMP‐9, have been identified in atherosclerotic plaques and have been directly associated with plaque remodelling and vulnerability. Cardiovascular disease (CVD) is related to insulin resistance (IR) and obesity, characterized by chang...
Saved in:
| Published in | European journal of clinical investigation Vol. 44; no. 10; pp. 951 - 957 |
|---|---|
| Main Authors | , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
Blackwell Publishing Ltd
01.10.2014
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Background
Matrix metalloproteinases (MMPs), especially MMP‐2 and MMP‐9, have been identified in atherosclerotic plaques and have been directly associated with plaque remodelling and vulnerability. Cardiovascular disease (CVD) is related to insulin resistance (IR) and obesity, characterized by changes in plasma levels of inflammatory markers, such as adiponectin and C‐reactive protein (CRP). Our aim was to evaluate the impact of both proteins on MMP‐2 and MMP‐9 behaviour in individuals with IR.
Materials and methods
Plasma MMP‐2 and MMP‐9 activity, adiponectin and hs‐CRP concentration and lipoprotein profile were determined in 52 patients with metabolic syndrome (MS) and 27 controls.
Results
Patients with MS presented significantly higher MMP‐2 activity than controls: 0·95 ± 0·12 vs. 0·77 ± 0·15 relative units (RU) (P < 0·001), while MMP‐9 activity was not detectable. MMP‐2 activity decreased across quartiles of adiponectin, being significantly reduced in individuals with the highest levels of adiponectin in compared with the lowest levels (0·75 ± 0·17 vs. 0·93 ± 0·09 RU, P < 0·005). This difference persisted significant after adjusting by obesity markers. MMP‐2 activity was significantly increased in individuals with the highest levels (G3) compared with those with the lowest levels (G1) of hs‐CRP (0·94 ± 0·12 vs. 0·86 ± 0·12, P = 0·041)
Conclusion
In this study, we observed that adiponectin levels predicted MMP‐2 plasma activity independently of obesity. This finding suggests that the inflammatory process, associated with the highest CVD risk, would be involved in MMPs vascular production. |
|---|---|
| AbstractList | Background
Matrix metalloproteinases (MMPs), especially MMP‐2 and MMP‐9, have been identified in atherosclerotic plaques and have been directly associated with plaque remodelling and vulnerability. Cardiovascular disease (CVD) is related to insulin resistance (IR) and obesity, characterized by changes in plasma levels of inflammatory markers, such as adiponectin and C‐reactive protein (CRP). Our aim was to evaluate the impact of both proteins on MMP‐2 and MMP‐9 behaviour in individuals with IR.
Materials and methods
Plasma MMP‐2 and MMP‐9 activity, adiponectin and hs‐CRP concentration and lipoprotein profile were determined in 52 patients with metabolic syndrome (MS) and 27 controls.
Results
Patients with MS presented significantly higher MMP‐2 activity than controls: 0·95 ± 0·12 vs. 0·77 ± 0·15 relative units (RU) (P < 0·001), while MMP‐9 activity was not detectable. MMP‐2 activity decreased across quartiles of adiponectin, being significantly reduced in individuals with the highest levels of adiponectin in compared with the lowest levels (0·75 ± 0·17 vs. 0·93 ± 0·09 RU, P < 0·005). This difference persisted significant after adjusting by obesity markers. MMP‐2 activity was significantly increased in individuals with the highest levels (G3) compared with those with the lowest levels (G1) of hs‐CRP (0·94 ± 0·12 vs. 0·86 ± 0·12, P = 0·041)
Conclusion
In this study, we observed that adiponectin levels predicted MMP‐2 plasma activity independently of obesity. This finding suggests that the inflammatory process, associated with the highest CVD risk, would be involved in MMPs vascular production. Matrix metalloproteinases (MMPs), especially MMP-2 and MMP-9, have been identified in atherosclerotic plaques and have been directly associated with plaque remodelling and vulnerability. Cardiovascular disease (CVD) is related to insulin resistance (IR) and obesity, characterized by changes in plasma levels of inflammatory markers, such as adiponectin and C-reactive protein (CRP). Our aim was to evaluate the impact of both proteins on MMP-2 and MMP-9 behaviour in individuals with IR. Plasma MMP-2 and MMP-9 activity, adiponectin and hs-CRP concentration and lipoprotein profile were determined in 52 patients with metabolic syndrome (MS) and 27 controls. Patients with MS presented significantly higher MMP-2 activity than controls: 0·95 ± 0·12 vs. 0·77 ± 0·15 relative units (RU) (P < 0·001), while MMP-9 activity was not detectable. MMP-2 activity decreased across quartiles of adiponectin, being significantly reduced in individuals with the highest levels of adiponectin in compared with the lowest levels (0·75 ± 0·17 vs. 0·93 ± 0·09 RU, P < 0·005). This difference persisted significant after adjusting by obesity markers. MMP-2 activity was significantly increased in individuals with the highest levels (G3) compared with those with the lowest levels (G1) of hs-CRP (0·94 ± 0·12 vs. 0·86 ± 0·12, P = 0·041) CONCLUSION: In this study, we observed that adiponectin levels predicted MMP-2 plasma activity independently of obesity. This finding suggests that the inflammatory process, associated with the highest CVD risk, would be involved in MMPs vascular production. Abstract Background Matrix metalloproteinases ( MMP s), especially MMP ‐2 and MMP ‐9, have been identified in atherosclerotic plaques and have been directly associated with plaque remodelling and vulnerability. Cardiovascular disease (CVD) is related to insulin resistance ( IR ) and obesity, characterized by changes in plasma levels of inflammatory markers, such as adiponectin and C‐reactive protein ( CRP ). Our aim was to evaluate the impact of both proteins on MMP ‐2 and MMP ‐9 behaviour in individuals with IR . Materials and methods Plasma MMP ‐2 and MMP ‐9 activity, adiponectin and hs‐ CRP concentration and lipoprotein profile were determined in 52 patients with metabolic syndrome ( MS ) and 27 controls. Results Patients with MS presented significantly higher MMP ‐2 activity than controls: 0·95 ± 0·12 vs. 0·77 ± 0·15 relative units ( RU ) ( P < 0·001), while MMP ‐9 activity was not detectable. MMP ‐2 activity decreased across quartiles of adiponectin, being significantly reduced in individuals with the highest levels of adiponectin in compared with the lowest levels (0·75 ± 0·17 vs. 0·93 ± 0·09 RU , P < 0·005). This difference persisted significant after adjusting by obesity markers. MMP ‐2 activity was significantly increased in individuals with the highest levels (G3) compared with those with the lowest levels (G1) of hs‐ CRP (0·94 ± 0·12 vs. 0·86 ± 0·12, P = 0·041) Conclusion In this study, we observed that adiponectin levels predicted MMP ‐2 plasma activity independently of obesity. This finding suggests that the inflammatory process, associated with the highest CVD risk, would be involved in MMP s vascular production. BACKGROUNDMatrix metalloproteinases (MMPs), especially MMP-2 and MMP-9, have been identified in atherosclerotic plaques and have been directly associated with plaque remodelling and vulnerability. Cardiovascular disease (CVD) is related to insulin resistance (IR) and obesity, characterized by changes in plasma levels of inflammatory markers, such as adiponectin and C-reactive protein (CRP). Our aim was to evaluate the impact of both proteins on MMP-2 and MMP-9 behaviour in individuals with IR.MATERIALS AND METHODSPlasma MMP-2 and MMP-9 activity, adiponectin and hs-CRP concentration and lipoprotein profile were determined in 52 patients with metabolic syndrome (MS) and 27 controls.RESULTSPatients with MS presented significantly higher MMP-2 activity than controls: 0·95 ± 0·12 vs. 0·77 ± 0·15 relative units (RU) (P < 0·001), while MMP-9 activity was not detectable. MMP-2 activity decreased across quartiles of adiponectin, being significantly reduced in individuals with the highest levels of adiponectin in compared with the lowest levels (0·75 ± 0·17 vs. 0·93 ± 0·09 RU, P < 0·005). This difference persisted significant after adjusting by obesity markers. MMP-2 activity was significantly increased in individuals with the highest levels (G3) compared with those with the lowest levels (G1) of hs-CRP (0·94 ± 0·12 vs. 0·86 ± 0·12, P = 0·041) CONCLUSION: In this study, we observed that adiponectin levels predicted MMP-2 plasma activity independently of obesity. This finding suggests that the inflammatory process, associated with the highest CVD risk, would be involved in MMPs vascular production. |
| Author | Schreier, Laura Berg, Gabriela Miksztowicz, Verónica Fernandez Machulsky, Nahuel Lucero, Diego Fassio, Eduardo |
| Author_xml | – sequence: 1 givenname: Verónica surname: Miksztowicz fullname: Miksztowicz, Verónica organization: Laboratory of Lipids and Atherosclerosis, Department of Clinical Biochemistry, Faculty of Pharmacy and Biochemistry, Institute of Physiopathology and Clinical Biochemistry, University of Buenos Aires, Buenos Aires, Argentina – sequence: 2 givenname: Nahuel surname: Fernandez Machulsky fullname: Fernandez Machulsky, Nahuel organization: Laboratory of Lipids and Atherosclerosis, Department of Clinical Biochemistry, Faculty of Pharmacy and Biochemistry, Institute of Physiopathology and Clinical Biochemistry, University of Buenos Aires, Buenos Aires, Argentina – sequence: 3 givenname: Diego surname: Lucero fullname: Lucero, Diego organization: Laboratory of Lipids and Atherosclerosis, Department of Clinical Biochemistry, Faculty of Pharmacy and Biochemistry, Institute of Physiopathology and Clinical Biochemistry, University of Buenos Aires, Buenos Aires, Argentina – sequence: 4 givenname: Eduardo surname: Fassio fullname: Fassio, Eduardo organization: Department of Gastroenterology, National Hospital Prof. A. Posadas, Buenos Aires, Argentina – sequence: 5 givenname: Laura surname: Schreier fullname: Schreier, Laura organization: Laboratory of Lipids and Atherosclerosis, Department of Clinical Biochemistry, Faculty of Pharmacy and Biochemistry, Institute of Physiopathology and Clinical Biochemistry, University of Buenos Aires, Buenos Aires, Argentina – sequence: 6 givenname: Gabriela surname: Berg fullname: Berg, Gabriela email: gaberg@ffyb.uba.ar organization: Laboratory of Lipids and Atherosclerosis, Department of Clinical Biochemistry, Faculty of Pharmacy and Biochemistry, Institute of Physiopathology and Clinical Biochemistry, University of Buenos Aires, Buenos Aires, Argentina |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/25145771$$D View this record in MEDLINE/PubMed |
| BookMark | eNp1kMtOwzAQRS1URB-w4AdQlrBI67HzaCQ2VVVKUctLoC4tx5lIhjQJcQrk7zGk7Y5ZzEgzZ87i9kknL3Ik5BzoEGyNUOkhMM7GR6QHPPBdxgPWIT1KwXNZFLIu6RvzRikdA2cnpMt88PwwhB65niS6tDZV69wpK0y0qo2zWj26zJF2-anrxtF5giXaltdZ4xSpU8Ro7OGUHKcyM3i2mwPyejN7md66y4f5YjpZusoLvLGbejJG8CgEMpSxFzDOExWlTNGEqnEUIYUwYlR5sUrSFCWLMWZREnGgEDPf5wNy2XrLqvjYoqnFRhuFWSZzLLZGgB8EQKOQc4tetaiqCmMqTEVZ6Y2sGgFU_IYlbFjiLyzLXuy023iDyYHcp2OBUQt86Qyb_01iNl3slW77oU2N34cPWb2LIOShL9b3c7FaL5_nT3e-AP4DarGDZA |
| CitedBy_id | crossref_primary_10_1515_hmbci_2018_0037 crossref_primary_10_1177_0003319714557353 crossref_primary_10_1038_s41598_021_99577_2 crossref_primary_10_1038_s41598_022_08041_2 crossref_primary_10_1155_2017_6198526 crossref_primary_10_2147_NSS_S459136 crossref_primary_10_3390_cells8020158 crossref_primary_10_3390_ijms222111703 crossref_primary_10_1016_j_bbrc_2015_02_054 |
| Cites_doi | 10.1586/14779072.5.2.265 10.1016/j.biochi.2012.06.008 10.1016/j.cca.2011.06.013 10.1016/j.ecl.2008.06.007 10.1161/01.CIR.0000058700.41738.12 10.1016/j.arcmed.2008.10.011 10.1016/S0140-6736(05)66378-7 10.2337/diabetes.54.3.795 10.2337/db08-1098 10.1016/j.cca.2006.12.006 10.1161/01.CIR.0000127953.98131.ED 10.25011/cim.v32i2.6030 10.1016/j.cardiores.2005.12.002 10.1016/j.numecd.2013.08.007 10.2478/s11658-010-0027-z 10.1016/j.biochi.2012.06.030 10.1016/j.dsx.2013.10.005 10.1046/j.1463-1326.2003.00290.x 10.3109/00365510902912747 10.1146/annurev.nutr.24.012003.132155 10.1002/jcb.23059 10.1016/j.metabol.2008.06.001 10.1016/j.cca.2010.09.025 10.1001/jama.285.19.2486 10.1016/j.ijcard.2012.10.040 10.1253/circj.CJ-09-0057 10.1016/j.cca.2009.02.013 10.3109/13697137.2012.667174 |
| ContentType | Journal Article |
| Copyright | 2014 Stichting European Society for Clinical Investigation Journal Foundation 2014 Stichting European Society for Clinical Investigation Journal Foundation. |
| Copyright_xml | – notice: 2014 Stichting European Society for Clinical Investigation Journal Foundation – notice: 2014 Stichting European Society for Clinical Investigation Journal Foundation. |
| DBID | BSCLL CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 |
| DOI | 10.1111/eci.12328 |
| DatabaseName | Istex Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic |
| DatabaseTitleList | MEDLINE CrossRef MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1365-2362 |
| EndPage | 957 |
| ExternalDocumentID | 10_1111_eci_12328 25145771 ECI12328 ark_67375_WNG_MWLRGQJ5_1 |
| Genre | article Research Support, Non-U.S. Gov't Journal Article |
| GrantInformation_xml | – fundername: University of Buenos Aires funderid: 200200100041 |
| GroupedDBID | --- -~X .3N .55 .GA .GJ .Y3 05W 0R~ 10A 1OB 1OC 29G 31~ 33P 36B 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5HH 5LA 5RE 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AANLZ AAONW AASGY AAXRX AAZKR ABCQN ABCUV ABDBF ABEML ABLJU ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACGFS ACGOF ACIWK ACMXC ACPOU ACPRK ACSCC ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN ADZOD AEEZP AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFEBI AFFNX AFFPM AFGKR AFPWT AFRAH AFZJQ AHBTC AHEFC AIACR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BSCLL BY8 C45 CAG COF CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DU5 DUUFO EAD EAP EAS EBB EBC EBD EBS EBX EJD EMB EMK EMOBN EPT ESX EX3 F00 F01 F04 F5P FEDTE FUBAC FZ0 G-S G.N GODZA H.X HF~ HGLYW HVGLF HZI HZ~ IHE IX1 J0M K48 KBYEO LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK0 MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ O66 O9- OIG OVD P2P P2W P2X P2Z P4B P4D PALCI Q.N Q11 QB0 Q~Q R.K RIWAO RJQFR ROL RX1 SAMSI SUPJJ SV3 TEORI TUS UB1 W8V W99 WBKPD WH7 WHWMO WIH WIJ WIK WOHZO WOW WQJ WRC WUP WVDHM WXI WXSBR X7M XG1 YFH ZGI ZXP ZZTAW ~IA ~WT CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 |
| ID | FETCH-LOGICAL-c4648-f4abe14016a7ab46233dc9f2c0d0c899e017920c4bcdffea2beb29d93101b2553 |
| IEDL.DBID | DR2 |
| ISSN | 0014-2972 |
| IngestDate | Fri Aug 16 06:17:59 EDT 2024 Fri Aug 23 02:29:53 EDT 2024 Sat Sep 28 08:03:07 EDT 2024 Sat Aug 24 00:41:25 EDT 2024 Wed Oct 30 09:57:08 EDT 2024 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 10 |
| Keywords | MMP-2 obesity Adiponectin |
| Language | English |
| License | 2014 Stichting European Society for Clinical Investigation Journal Foundation. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c4648-f4abe14016a7ab46233dc9f2c0d0c899e017920c4bcdffea2beb29d93101b2553 |
| Notes | ark:/67375/WNG-MWLRGQJ5-1 istex:CF2396F65A10158A9B88DF13E5C75198384CF32C ArticleID:ECI12328 University of Buenos Aires - No. 200200100041 ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | https://ri.conicet.gov.ar/bitstream/11336/30346/2/CONICET_Digital_Nro.e9c0aec7-87f7-4aba-ae0a-fa6b1bd65a55_A.pdf |
| PMID | 25145771 |
| PQID | 1566109733 |
| PQPubID | 23479 |
| PageCount | 7 |
| ParticipantIDs | proquest_miscellaneous_1566109733 crossref_primary_10_1111_eci_12328 pubmed_primary_25145771 wiley_primary_10_1111_eci_12328_ECI12328 istex_primary_ark_67375_WNG_MWLRGQJ5_1 |
| PublicationCentury | 2000 |
| PublicationDate | October 2014 |
| PublicationDateYYYYMMDD | 2014-10-01 |
| PublicationDate_xml | – month: 10 year: 2014 text: October 2014 |
| PublicationDecade | 2010 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England |
| PublicationTitle | European journal of clinical investigation |
| PublicationTitleAlternate | Eur J Clin Invest |
| PublicationYear | 2014 |
| Publisher | Blackwell Publishing Ltd |
| Publisher_xml | – name: Blackwell Publishing Ltd |
| References | Boden G. Obesity and free fatty acids. Endocrinol Metab Clin North Am 2008;37:635-46. Gonçalves FM, Jacob-Ferreira AL, Gomes VA, Casella-Filho A, Chagas AC, Marcaccini AM et al. Increased circulating levels of matrix metalloproteinase (MMP)-8, MMP-9, and pro-inflammatory markers in patients with metabolic syndrome. Clin Chim Acta 2009;403:173-7. Ng TW, Watts GF, Farvid MS, Chan DC, Barrett PH. Adipocytokines and VLDL metabolism: independent regulatory effects of adiponectin, insulin resistance, and fat compartments on VLDL apolipoprotein B-100 kinetics? Diabetes 2005;54:795-802. Gummesson A, Hagg D, Olson FJ, Hulthe J, Carlsson LM, Fagerberg B. Adipose tissue is not an important source for matrix metalloproteinase-9 in the circulation. Scand J Clin Lab Invest 2009;69:636-42. Blankenberg S, Rupprecht HJ, Poirier O, Bickel C, Smieja M, Hafner G et al. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation 2003;107:1579-85. Johnson JL. Matrix metalloproteinases: influence on smooth muscle cells and atherosclerotic plaque stability. Expert Rev Cardiovasc Ther 2007;5:265-82. Bonneau GA, Pedrozo WR, Berg G. Adiponectin and waist circumference as predictors of insulin-resistance in women. Diabetes Metab Syndr 2014;8:3-7. Miksztowicz V, Morales C, Zago V, Friedman S, Schreier L, Berg G. Effect of insulin-resistance on circulating and adipose tissue MMP-2 and MMP-9 activity in rats fed a sucrose-rich diet. Nut Metab Cardiovas Dis 2014;24:294-300. Wu X, Yan Q, Zhang Z, Du G, Wan X. Acrp30 inhibits leptin induced metastasis by downregulating the JAK/STAT3 pathway via AMPK activation in aggressive SPEC-2 endometrial cancer cells. Oncol Rep 2012;27:1488-96. Aquilante CL, Beitelshees AL, Zineh I. Correlates of serum matrix metalloproteinase- 8 (MMP-8) concentrations in non-diabetic subjects without cardiovascular disease. Clin Chim Acta 2007;379:48-52. Tong KM, Chen CP, Huang KC, Shieh DC, Cheng HC, Tzeng CY et al. Adiponectin increases MMP-3 expression in human chondrocytes through AdipoR1 signaling pathway. J Cell Biochem 2011;112:1431-40. Muzzio ML, Miksztowicz V, Brites F, Aguilar D, Repetto EM, Wikinski R et al. Metalloproteases 2 and 9, Lp-PLA(2) and lipoprotein profile in coronary patients. Arch Med Res 2009;40:48-53. Derosa G, Maffioli P, D'Angelo A, Salvadeo SA, Ferrari I, Fogari E et al. Evaluation of metalloproteinase 2 and 9 levels and their inhibitors in combined dyslipidemia. Clin Invest Med 2009;32:E124-32. Haffner SM, Cassells HB. Metabolic syndrome-a new risk factor of coronary heart disease? Diabetes Obes Metab 2003;5:359-70. Ohash K, Ouchi N, Matsuzawa Y. Anti-inflammatory and anti-atherogenic properties of adiponectina. Biochimie 2012;94:2137-42. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. (Adult Treatment Panel III). JAMA 2001;285:2486-97. Shibata R, Ouchi N, Murohara T. Adiponectin and cardiovascular disease. Circ J 2009;73:608-14. Miksztowicz V, Siseles N, Fernandez Machulsky N, Schreier L, Berg G. Increase in MMP-2 activity in overweight and obese women is associated with menopausal status. Climacteric 2012;15:602-6. Li Z, Li L, Zielke HR, Cheng L, Xiao R, Crow MT et al. Increased expression of 72-kd type IV collagenase (MMP-2) in human aortic atherosclerosis lesions. Am J Pathol 1996;148:121-8. Miksztowicz V, Muzzio ML, Royer M, Prada M, Wikinski R, Schreier L et al. Increased plasma activity of metalloproteinase 2 in women with metabolic syndrome. Metabolism 2008;57:1493-6. Cimmino G, Ragni M, Cirillo P, Petrillo G, Loffredo F, Chiariello M et al. C-reactive protein induces expression of matrix metalloproteinase-9: a possible link between inflammation and plaque rupture. Int J Cardiol 2013;168:981-6. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005;365:1415-28. Lucero D, Zago V, López GI, Graffigna M, Fainboim H, Miksztowicz V et al. Pro-inflammatory and atherogenic circulating factors in non-alcoholic fatty liver disease associated to metabolic syndrome. Clin Chim Acta 2011;412:143-7. Reaven GM. The insulin resistance syndrome: definition and dietary approaches to treatment. Annu Rev Nutr 2005;25:391-406. Villarreal-Molina MT, Antuna-Puente B. Adiponectin: anti-inflammatory and cardioprotective effects. Biochimie 2012;94:2143-9. Schram K1, De Girolamo S, Madani S, Munoz D, Thong F, Sweeney G. Leptin regulates MMP-2, TIMP-1 and collagen synthesis via p38 MAPK in HL-1 murine cardiomyocytes. Cell Mol Biol Lett 2010;15:551-63. Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res 2006;69:562-73. Berg G, Miksztowicz V, Schreier L. Metalloproteinases in metabolic syndrome. Clin Chim Acta 2011;412:1731-9. Pasarica M, Sereda OR, Redman LM, Albarado DC, Hymel DT, Roan LE et al. Reduced adipose tissue oxygenation in human obesity: evidence for rarefaction, macrophage chemotaxis, and inflammation without an angiogenic response. Diabetes 2009;58:718e25. Kumada M, Kihara S, Ouchi N, Kobayashi H, Okamoto Y, Ohashi K et al. Adiponectin specifically increased tissue inhibitor of metalloproteinase-1 through interleukin-10 expression in human macrophages. Circulation 2004;109:2046-9. 2011; 412 2009; 69 2009; 40 2010; 15 2001; 285 2008; 37 2008; 57 2013; 168 2014; 24 2012; 15 1996; 148 2004; 109 2011; 112 2005; 25 2012; 94 2007; 379 2009; 58 2003; 107 2009; 73 2009; 32 2005; 365 2006; 69 2003; 5 2005; 54 2007; 5 2012; 27 2014; 8 2009; 403 e_1_2_7_6_1 e_1_2_7_5_1 e_1_2_7_4_1 e_1_2_7_9_1 e_1_2_7_8_1 e_1_2_7_7_1 e_1_2_7_19_1 e_1_2_7_18_1 e_1_2_7_17_1 e_1_2_7_16_1 e_1_2_7_2_1 e_1_2_7_15_1 e_1_2_7_14_1 e_1_2_7_13_1 e_1_2_7_12_1 Li Z (e_1_2_7_3_1) 1996; 148 e_1_2_7_11_1 e_1_2_7_10_1 e_1_2_7_26_1 e_1_2_7_27_1 e_1_2_7_28_1 e_1_2_7_29_1 e_1_2_7_30_1 e_1_2_7_25_1 e_1_2_7_31_1 Wu X (e_1_2_7_23_1) 2012; 27 e_1_2_7_22_1 e_1_2_7_21_1 e_1_2_7_20_1 Derosa G (e_1_2_7_24_1) 2009; 32 |
| References_xml | – volume: 57 start-page: 1493 year: 2008 end-page: 6 article-title: Increased plasma activity of metalloproteinase 2 in women with metabolic syndrome publication-title: Metabolism – volume: 73 start-page: 608 year: 2009 end-page: 14 article-title: Adiponectin and cardiovascular disease publication-title: Circ J – volume: 412 start-page: 1731 year: 2011 end-page: 9 article-title: Metalloproteinases in metabolic syndrome publication-title: Clin Chim Acta – volume: 365 start-page: 1415 year: 2005 end-page: 28 article-title: The metabolic syndrome publication-title: Lancet – volume: 5 start-page: 265 year: 2007 end-page: 82 article-title: Matrix metalloproteinases: influence on smooth muscle cells and atherosclerotic plaque stability publication-title: Expert Rev Cardiovasc Ther – volume: 15 start-page: 551 year: 2010 end-page: 63 article-title: Leptin regulates MMP‐2, TIMP‐1 and collagen synthesis via p38 MAPK in HL‐1 murine cardiomyocytes publication-title: Cell Mol Biol Lett – volume: 412 start-page: 143 year: 2011 end-page: 7 article-title: Pro‐inflammatory and atherogenic circulating factors in non‐alcoholic fatty liver disease associated to metabolic syndrome publication-title: Clin Chim Acta – volume: 107 start-page: 1579 year: 2003 end-page: 85 article-title: Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease publication-title: Circulation – volume: 69 start-page: 636 year: 2009 end-page: 42 article-title: Adipose tissue is not an important source for matrix metalloproteinase‐9 in the circulation publication-title: Scand J Clin Lab Invest – volume: 94 start-page: 2143 year: 2012 end-page: 9 article-title: Adiponectin: anti‐inflammatory and cardioprotective effects publication-title: Biochimie – volume: 403 start-page: 173 year: 2009 end-page: 7 article-title: Increased circulating levels of matrix metalloproteinase (MMP)‐8, MMP‐9, and pro‐inflammatory markers in patients with metabolic syndrome publication-title: Clin Chim Acta – volume: 37 start-page: 635 year: 2008 end-page: 46 article-title: Obesity and free fatty acids publication-title: Endocrinol Metab Clin North Am – volume: 58 start-page: 718e25 year: 2009 article-title: Reduced adipose tissue oxygenation in human obesity: evidence for rarefaction, macrophage chemotaxis, and inflammation without an angiogenic response publication-title: Diabetes – volume: 27 start-page: 1488 year: 2012 end-page: 96 article-title: Acrp30 inhibits leptin induced metastasis by downregulating the JAK/STAT3 pathway via AMPK activation in aggressive SPEC‐2 endometrial cancer cells publication-title: Oncol Rep – volume: 148 start-page: 121 year: 1996 end-page: 8 article-title: Increased expression of 72‐kd type IV collagenase (MMP‐2) in human aortic atherosclerosis lesions publication-title: Am J Pathol – volume: 15 start-page: 602 year: 2012 end-page: 6 article-title: Increase in MMP‐2 activity in overweight and obese women is associated with menopausal status publication-title: Climacteric – volume: 25 start-page: 391 year: 2005 end-page: 406 article-title: The insulin resistance syndrome: definition and dietary approaches to treatment publication-title: Annu Rev Nutr – volume: 109 start-page: 2046 year: 2004 end-page: 9 article-title: Adiponectin specifically increased tissue inhibitor of metalloproteinase‐1 through interleukin‐10 expression in human macrophages publication-title: Circulation – volume: 379 start-page: 48 year: 2007 end-page: 52 article-title: Correlates of serum matrix metalloproteinase‐ 8 (MMP‐8) concentrations in non‐diabetic subjects without cardiovascular disease publication-title: Clin Chim Acta – volume: 112 start-page: 1431 year: 2011 end-page: 40 article-title: Adiponectin increases MMP‐3 expression in human chondrocytes through AdipoR1 signaling pathway publication-title: J Cell Biochem – volume: 94 start-page: 2137 year: 2012 end-page: 42 article-title: Anti‐inflammatory and anti‐atherogenic properties of adiponectina publication-title: Biochimie – volume: 54 start-page: 795 year: 2005 end-page: 802 article-title: Adipocytokines and VLDL metabolism: independent regulatory effects of adiponectin, insulin resistance, and fat compartments on VLDL apolipoprotein B‐100 kinetics? publication-title: Diabetes – volume: 40 start-page: 48 year: 2009 end-page: 53 article-title: Metalloproteases 2 and 9, Lp‐PLA(2) and lipoprotein profile in coronary patients publication-title: Arch Med Res – volume: 69 start-page: 562 year: 2006 end-page: 73 article-title: Structure and function of matrix metalloproteinases and TIMPs publication-title: Cardiovasc Res – volume: 285 start-page: 2486 year: 2001 end-page: 97 article-title: Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. (Adult Treatment Panel III) publication-title: JAMA – volume: 32 start-page: E124 year: 2009 end-page: 32 article-title: Evaluation of metalloproteinase 2 and 9 levels and their inhibitors in combined dyslipidemia publication-title: Clin Invest Med – volume: 8 start-page: 3 year: 2014 end-page: 7 article-title: Adiponectin and waist circumference as predictors of insulin‐resistance in women publication-title: Diabetes Metab Syndr – volume: 5 start-page: 359 year: 2003 end-page: 70 article-title: Metabolic syndrome—a new risk factor of coronary heart disease? publication-title: Diabetes Obes Metab – volume: 24 start-page: 294 year: 2014 end-page: 300 article-title: Effect of insulin‐resistance on circulating and adipose tissue MMP‐2 and MMP‐9 activity in rats fed a sucrose‐rich diet publication-title: Nut Metab Cardiovas Dis – volume: 168 start-page: 981 year: 2013 end-page: 6 article-title: C‐reactive protein induces expression of matrix metalloproteinase‐9: a possible link between inflammation and plaque rupture publication-title: Int J Cardiol – ident: e_1_2_7_18_1 doi: 10.1586/14779072.5.2.265 – volume: 148 start-page: 121 year: 1996 ident: e_1_2_7_3_1 article-title: Increased expression of 72‐kd type IV collagenase (MMP‐2) in human aortic atherosclerosis lesions publication-title: Am J Pathol contributor: fullname: Li Z – ident: e_1_2_7_11_1 doi: 10.1016/j.biochi.2012.06.008 – ident: e_1_2_7_14_1 doi: 10.1016/j.cca.2011.06.013 – ident: e_1_2_7_6_1 doi: 10.1016/j.ecl.2008.06.007 – ident: e_1_2_7_4_1 doi: 10.1161/01.CIR.0000058700.41738.12 – ident: e_1_2_7_17_1 doi: 10.1016/j.arcmed.2008.10.011 – ident: e_1_2_7_9_1 doi: 10.1016/S0140-6736(05)66378-7 – ident: e_1_2_7_31_1 doi: 10.2337/diabetes.54.3.795 – ident: e_1_2_7_5_1 doi: 10.2337/db08-1098 – ident: e_1_2_7_20_1 doi: 10.1016/j.cca.2006.12.006 – ident: e_1_2_7_13_1 doi: 10.1161/01.CIR.0000127953.98131.ED – volume: 32 start-page: E124 year: 2009 ident: e_1_2_7_24_1 article-title: Evaluation of metalloproteinase 2 and 9 levels and their inhibitors in combined dyslipidemia publication-title: Clin Invest Med doi: 10.25011/cim.v32i2.6030 contributor: fullname: Derosa G – ident: e_1_2_7_2_1 doi: 10.1016/j.cardiores.2005.12.002 – ident: e_1_2_7_28_1 doi: 10.1016/j.numecd.2013.08.007 – ident: e_1_2_7_29_1 doi: 10.2478/s11658-010-0027-z – ident: e_1_2_7_21_1 doi: 10.1016/j.biochi.2012.06.030 – ident: e_1_2_7_25_1 doi: 10.1016/j.dsx.2013.10.005 – volume: 27 start-page: 1488 year: 2012 ident: e_1_2_7_23_1 article-title: Acrp30 inhibits leptin induced metastasis by downregulating the JAK/STAT3 pathway via AMPK activation in aggressive SPEC‐2 endometrial cancer cells publication-title: Oncol Rep contributor: fullname: Wu X – ident: e_1_2_7_10_1 doi: 10.1046/j.1463-1326.2003.00290.x – ident: e_1_2_7_27_1 doi: 10.3109/00365510902912747 – ident: e_1_2_7_8_1 doi: 10.1146/annurev.nutr.24.012003.132155 – ident: e_1_2_7_22_1 doi: 10.1002/jcb.23059 – ident: e_1_2_7_7_1 doi: 10.1016/j.metabol.2008.06.001 – ident: e_1_2_7_30_1 doi: 10.1016/j.cca.2010.09.025 – ident: e_1_2_7_16_1 doi: 10.1001/jama.285.19.2486 – ident: e_1_2_7_15_1 doi: 10.1016/j.ijcard.2012.10.040 – ident: e_1_2_7_12_1 doi: 10.1253/circj.CJ-09-0057 – ident: e_1_2_7_19_1 doi: 10.1016/j.cca.2009.02.013 – ident: e_1_2_7_26_1 doi: 10.3109/13697137.2012.667174 |
| SSID | ssj0008132 |
| Score | 2.1968825 |
| Snippet | Background
Matrix metalloproteinases (MMPs), especially MMP‐2 and MMP‐9, have been identified in atherosclerotic plaques and have been directly associated with... Matrix metalloproteinases (MMPs), especially MMP-2 and MMP-9, have been identified in atherosclerotic plaques and have been directly associated with plaque... Abstract Background Matrix metalloproteinases ( MMP s), especially MMP ‐2 and MMP ‐9, have been identified in atherosclerotic plaques and have been directly... BACKGROUNDMatrix metalloproteinases (MMPs), especially MMP-2 and MMP-9, have been identified in atherosclerotic plaques and have been directly associated with... |
| SourceID | proquest crossref pubmed wiley istex |
| SourceType | Aggregation Database Index Database Publisher |
| StartPage | 951 |
| SubjectTerms | Adiponectin Adiponectin - physiology Adult Aged Biomarkers - metabolism C-Reactive Protein - physiology Case-Control Studies Female Humans Insulin Resistance - physiology Lipid Metabolism - physiology Lipoproteins - metabolism Male Matrix Metalloproteinase 2 - metabolism Metabolic Syndrome - enzymology Middle Aged MMP-2 obesity Obesity - enzymology Young Adult |
| Title | Adiponectin predicts MMP-2 activity independently of obesity |
| URI | https://api.istex.fr/ark:/67375/WNG-MWLRGQJ5-1/fulltext.pdf https://onlinelibrary.wiley.com/doi/abs/10.1111%2Feci.12328 https://www.ncbi.nlm.nih.gov/pubmed/25145771 https://search.proquest.com/docview/1566109733 |
| Volume | 44 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3bSsQwEB1EQXzxfllvVBHxpUubpNsWQRDvYkVF0QchNGkCy0p32e2C-uQn-I1-iZl2Wy8oiG-lJCWdySRnkpkzABuUeSHxEseWQahsZKSzAx37tvKIokEgCGWYOxydN45v2OmddzcE22UuTMEPUR24oWXk6zUaeCx6n4xcyWYd8QAm-rrUx3Cu_asP6qjApQVTuMtsEvpkwCqEUTxVzy970QiK9fEnoPkVt-Ybz-EE3JdDLuJNWvV-Jury-Rub4z__aRLGB4DU2i1m0BQMqXQaRqPBlfsM7OwmzU47xXUxtTpdfJ_1rCi6eHt5JRamRWD1CatZldPNHp6strbaRcWBWbg5PLjeO7YHRRdsyRossDWLhUKvqxH7sWAGHdFEhppIJ3GMPkOFJkwcyYRMtFYxEcY3D5PQwERXGP-EzsFwaka1AJZvFK2F2SIdYUBEoAOXKUkUYxLzgT1dg_VS_LxTcGvw0icxkuC5JGqwmSumahF3WxiM5nv89vyIR7dnV0eXpx53a7BWao4bE8F7jzhV7X6Po4uKF-2U1mC-UGn1NQPvmOf7pvdWrpjfB8IP9k7yh8W_N12CMYITMA_-W4bhrNtXKwbEZGI1n63vxOvqYA |
| link.rule.ids | 315,783,787,1378,27938,27939,46308,46732 |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1tS-QwEB58AfXL6al37nkvVUT80qVN0m0Kx4H4tup2UVH0i4QmTWDx6C5rF-7ukz_B33i_5DLttp6iIH4rJSnpTCZ5Jpl5BmCDsiAiQeq5ikfaRUY6l5skdHVANOVcEsowdzjuttoX7OgquJqA71UuTMkPUR-4oWUU6zUaOB5I_2flWvWaCAj4JExbc6dYv2D37IE8ivu05Ar3mUuikIx5hTCOp-76aDeaRsH-eg5qPkauxdazPw_X1aDLiJOb5iiXTfXnCZ_jW_9qAd6NMamzXU6i9zChs0WYice37kvwYzvtDfoZLo2ZMxji-_zWieOTv3f3xMHMCCxA4fTqirr5z99O3zj9sujAMlzs753vtN1x3QVXsRbjrmGJ1Oh4tZIwkcwCJJqqyBDlpZ5VaaTRiomnmFSpMToh0rrnURpZpOhL66LQDzCV2VGtgBNaXRtpd0lPWhzBDfeZVkQzpjAlODANWK_kLwYlvYao3BIrCVFIogGbhWbqFsnwBuPRwkBcdg9EfNk5Ozg9CoTfgLVKdcJaCV59JJnuj24Feql4105pAz6WOq2_ZhEeC8LQ9t4qNPPyQMTezmHx8On1Tb_BbPs87ojOYfd4FeYIzsYiFvAzTOXDkf5iMU0uvxZT9x9tiu56 |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1tS-QwEB58AfGL58up66nXk0P80qVN0m3KgSDq-nJ2UTlxPwihSRNYlO6yduHuPt1PuN_oLzHTbqseJ4jfSklKOpNJnklmngH4SlkQkSD1XMUj7SIjnctNEro6IJpyLgllmDscd1rHV-y0G3Qn4FuVC1PyQ9QHbmgZxXqNBj5IzTMj16rXRDzAJ2GataiH8VwHl0_cUdynJVW4z1wShWRMK4RhPHXXF5vRNMr15_-Q5kvgWuw87Q9wU425DDi5bY5y2VS__6FzfOdPzcPcGJE6e-UUWoAJnS3CTDy-c1-C3b20N-hnuDBmzmCI7_N7J47PH_78JQ7mRWD5CadX19PN7345feP0y5IDH-Gqffhj_9gdV11wFWsx7hqWSI1uVysJE8ksPKKpigxRXupZhUYabZh4ikmVGqMTIq1zHqWRxYm-tA4KXYapzI5qFZzQatpIu0d60qIIbrjPtCKaMYUJwYFpwFYlfjEoyTVE5ZRYSYhCEg3YLhRTt0iGtxiNFgbiunMk4uuzy6OL00D4DfhSaU5YG8GLjyTT_dG9QB8Vb9opbcBKqdL6axbfsSAMbe-dQjGvD0Qc7p8UD2tvb_oZZs4P2uLspPP9E8wSnItFIOA6TOXDkd6wgCaXm8XEfQSxxO0p |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Adiponectin+predicts+MMP-2+activity+independently+of+obesity&rft.jtitle=European+journal+of+clinical+investigation&rft.au=Miksztowicz%2C+Ver%C3%B3nica&rft.au=Fernandez+Machulsky%2C+Nahuel&rft.au=Lucero%2C+Diego&rft.au=Fassio%2C+Eduardo&rft.date=2014-10-01&rft.eissn=1365-2362&rft.volume=44&rft.issue=10&rft.spage=951&rft_id=info:doi/10.1111%2Feci.12328&rft_id=info%3Apmid%2F25145771&rft.externalDocID=25145771 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0014-2972&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0014-2972&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0014-2972&client=summon |